HBI announces approval of four Category III CPT codes
February 4, 2014

Nova Scotia – Halifax Biomedical Inc. (HBI), announces the approval by the American Medical Association (AMA) of four Category III CPT codes. These codes are used for the implantation of tantalum markers in anatomical structures, and for stereo-radiographic patient exams and image analysis.

I am very pleased to announce that the AMA approved, during their October 2013 Editorial Panel meeting, four Category III CPT codes: 0347T, 0348T, 0349T, and 0350T, which enable physicians and hospitals to describe and request coverage for the procedure of marking tissues with Halifax tantalum spheres, and for the practice of stereo-radiography in the spine, upper extremities, and lower extremities, respectively” said HBI’s VP of Clinical Research Services Robert Poggie, PhD. “Category III codes are an important first step to enable providers to be reimbursed for implementing our technology. This is a major step forward in our efforts to document the significant clinical and economic benefit of the Halifax program”, said HBI’s COO, John Simon.

“HBI is rapidly advancing precision imaging into the forefront of orthopaedic product validation based on evidenced based medicine with the highest precision metrics available. The approval of these Category III CPT codes by the AMA is an important milestone in our strategy to transform stereo-radiography from a research-only tool to widely adopted clinical practice” said HBI CEO Chad Munro.

This approval represents HBI’s principle achievement to date, providing an opportunity in the US market to further expansion and evidence-based research in preparation for Category I codes.
Halifax Biomedical Inc.
Halifax Biomedical Inc. (HBI) is an evidencebased Orthopaedic diagnostics company headquartered in Nova Scotia, Canada with US offices located in Cambridge, MA.

HBI is a world leading provider of micro-instability assessment services using very precise proprietary Stereo Radiography (SR) imaging technology (HALIFAX exams).

HBI focuses on two clinical problems: detection of implant loosening for total hip and knee replacements, and quantification of instability of the spinal column in patients with chronic low back pain.

For more information, please contact:

John Simon, COO
Email: john.simon@apps.halifaxbiomedical.com
Office: +1 (902) 945-2771
Fax: +1 (506) 645-1448

Canadian Mailing Address:
Halifax Biomedical Inc.
11493 Route 19
Mabou, Nova Scotia  B0E 1X0

US Mailing Address:
Halifax Biomedical Inc.
1 Broadway, 14th Floor
Cambridge, MA  02142  USA

www.apps.halifaxbiomedical.com